Literature DB >> 25054659

Oncolytic virotherapy for gliomas: steps toward the future.

Johanna K Kaufmann1, E Antonio Chiocca.   

Abstract

Entities:  

Mesh:

Year:  2013        PMID: 25054659      PMCID: PMC6136095          DOI: 10.2217/cns.13.35

Source DB:  PubMed          Journal:  CNS Oncol        ISSN: 2045-0907


× No keyword cloud information.
  32 in total

1.  Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma.

Authors:  Juergen Voges; Regina Reszka; Axel Gossmann; Claus Dittmar; Raphaela Richter; Guido Garlip; Lutz Kracht; Heinz H Coenen; Volker Sturm; Karl Wienhard; Wolf-Dieter Heiss; Andreas H Jacobs
Journal:  Ann Neurol       Date:  2003-10       Impact factor: 10.422

Review 2.  Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond.

Authors:  Johanna K Kaufmann; Dirk M Nettelbeck
Journal:  Trends Mol Med       Date:  2012-05-25       Impact factor: 11.951

3.  Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants.

Authors:  M Gromeier; L Alexander; E Wimmer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

4.  Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth.

Authors:  Sonia Guedan; Juan José Rojas; Alena Gros; Elena Mercade; Manel Cascallo; Ramon Alemany
Journal:  Mol Ther       Date:  2010-05-04       Impact factor: 11.454

5.  Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme.

Authors:  Arnold I Freeman; Zichria Zakay-Rones; John M Gomori; Eduard Linetsky; Linda Rasooly; Evgeniya Greenbaum; Shira Rozenman-Yair; Amos Panet; Eugene Libson; Charles S Irving; Eithan Galun; Tali Siegal
Journal:  Mol Ther       Date:  2005-10-28       Impact factor: 11.454

6.  Synergistic interaction between oncolytic viruses augments tumor killing.

Authors:  Fabrice Le Boeuf; Jean-Simon Diallo; J Andrea McCart; Steve Thorne; Theresa Falls; Marianne Stanford; Femina Kanji; Rebecca Auer; Christopher W Brown; Brian D Lichty; Kelley Parato; Harold Atkins; David Kirn; John C Bell
Journal:  Mol Ther       Date:  2010-03-16       Impact factor: 11.454

7.  Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses.

Authors:  Giulia Fulci; Laura Breymann; Davide Gianni; Kazuhiko Kurozomi; Sarah S Rhee; Jianhua Yu; Balveen Kaur; David N Louis; Ralph Weissleder; Michael A Caligiuri; E Antonio Chiocca
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-14       Impact factor: 11.205

8.  Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.

Authors:  Omar D Perez; Christopher R Logg; Kei Hiraoka; Oscar Diago; Ryan Burnett; Akihito Inagaki; Dawn Jolson; Karin Amundson; Taylor Buckley; Dan Lohse; Amy Lin; Cindy Burrascano; Carlos Ibanez; Noriyuki Kasahara; Harry E Gruber; Douglas J Jolly
Journal:  Mol Ther       Date:  2012-05-01       Impact factor: 11.454

9.  HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival.

Authors:  S Harrow; V Papanastassiou; J Harland; R Mabbs; R Petty; M Fraser; D Hadley; J Patterson; S M Brown; R Rampling
Journal:  Gene Ther       Date:  2004-11       Impact factor: 5.250

10.  A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.

Authors:  Peter Forsyth; Gloria Roldán; David George; Carla Wallace; Cheryl Ann Palmer; Don Morris; Gregory Cairncross; Maureen Vallee Matthews; James Markert; Yancey Gillespie; Matt Coffey; Brad Thompson; Mark Hamilton
Journal:  Mol Ther       Date:  2008-02-05       Impact factor: 11.454

View more
  3 in total

1.  In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells.

Authors:  L M E Berghauser Pont; R K Balvers; J J Kloezeman; M O Nowicki; W van den Bossche; A Kremer; H Wakimoto; B G van den Hoogen; S Leenstra; C M F Dirven; E A Chiocca; S E Lawler; M L M Lamfers
Journal:  Gene Ther       Date:  2015-07-21       Impact factor: 5.250

2.  A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model.

Authors:  Julius W Kim; Jason Miska; Jacob S Young; Aida Rashidi; J Robert Kane; Wojciech K Panek; Deepak Kanojia; Yu Han; Irina V Balyasnikova; Maciej S Lesniak
Journal:  Mol Ther Oncolytics       Date:  2017-05-06       Impact factor: 7.200

3.  Oncolytic Herpes Virus rRp450 Shows Efficacy in Orthotopic Xenograft Group 3/4 Medulloblastomas and Atypical Teratoid/Rhabdoid Tumors.

Authors:  Adam W Studebaker; Brian J Hutzen; Christopher R Pierson; Kellie B Haworth; Timothy P Cripe; Eric M Jackson; Jeffrey R Leonard
Journal:  Mol Ther Oncolytics       Date:  2017-05-25       Impact factor: 7.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.